{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T03:23:59Z","timestamp":1787369039571,"version":"build-2736575974"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03758-2","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T03:03:30Z","timestamp":1787367810000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Menopause and Menopausal Hormone Therapy on Liver\u2013Kidney\u2013Metabolic Health"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1645-9989","authenticated-orcid":false,"given":"Mohamad","family":"Jamalinia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9886-0698","authenticated-orcid":false,"given":"Amedeo","family":"Lonardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3888-0931","authenticated-orcid":false,"given":"Ralf","family":"Weiskirchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"issue":"10","key":"3758_CR1","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/17512433.2023.2259306","volume":"16","author":"A Lonardo","year":"2023","unstructured":"Lonardo A. The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: a narrative review focusing on principal risk modifiers. Expert Rev Clin Pharmacol. 2023;16(10):891\u2013911. https:\/\/doi.org\/10.1080\/17512433.2023.2259306.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"3758_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21165888","author":"A Lonardo","year":"2020","unstructured":"Lonardo A, Leoni S, Alswat KA, Fouad Y. History of nonalcoholic fatty liver disease. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21165888.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3758_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-63386-0","volume":"14","author":"C Cen","year":"2024","unstructured":"Cen C, Fan Z, Ding X, Tu X, Liu Y. Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: a national retrospective cohort study. Sci Rep. 2024;14(1):12645. https:\/\/doi.org\/10.1038\/s41598-024-63386-0.","journal-title":"Sci Rep"},{"key":"3758_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241511986","author":"M Kvandova","year":"2023","unstructured":"Kvandova M, Puzserova A, Balis P. Sexual dimorphism in cardiometabolic diseases: the role of AMPK. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241511986.","journal-title":"Int J Mol Sci"},{"issue":"16","key":"3758_CR5","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/circulationaha.109.192644","volume":"120","author":"KG Alberti","year":"2009","unstructured":"Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640\u20135. https:\/\/doi.org\/10.1161\/circulationaha.109.192644.","journal-title":"Circulation"},{"issue":"20","key":"3758_CR6","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/cir.0000000000001186","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023;148(20):1636\u201364. https:\/\/doi.org\/10.1161\/cir.0000000000001186.","journal-title":"Circulation"},{"issue":"9","key":"3758_CR7","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrendo.2017.56","volume":"13","author":"RCR Meex","year":"2017","unstructured":"Meex RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017;13(9):509\u201320. https:\/\/doi.org\/10.1038\/nrendo.2017.56.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"3758_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2023.101506","volume":"50","author":"J Bilson","year":"2024","unstructured":"Bilson J, Mantovani A, Byrne CD, Targher G. Steatotic liver disease, MASLD and risk of chronic kidney disease. Diabetes Metab. 2024;50(1):101506. https:\/\/doi.org\/10.1016\/j.diabet.2023.101506.","journal-title":"Diabetes Metab"},{"issue":"4","key":"3758_CR9","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","volume":"72","author":"CD Byrne","year":"2020","unstructured":"Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020;72(4):785\u2013801. https:\/\/doi.org\/10.1016\/j.jhep.2020.01.013.","journal-title":"J Hepatol"},{"issue":"11","key":"3758_CR10","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/s2468-1253(21)00308-3","volume":"6","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903\u201313. https:\/\/doi.org\/10.1016\/s2468-1253(21)00308-3.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3758_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2026.156549","volume":"178","author":"T Duo","year":"2026","unstructured":"Duo T, Wen Y, Bian Y, et al. Rising burden of MASLD and CKM syndrome in Asia: a decade of trends and future projections. Metabolism. 2026;178:156549. https:\/\/doi.org\/10.1016\/j.metabol.2026.156549.","journal-title":"Metabolism"},{"issue":"9","key":"3758_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf260","volume":"18","author":"F Moncho","year":"2025","unstructured":"Moncho F, Benlloch S, G\u00f3rriz JL. The impact of metabolic dysfunction-associated steatotic liver disease (MASH) on the high risk of cardiovascular disease in CKD: interconnections and management. Clin Kidney J. 2025;18(9):sfaf260. https:\/\/doi.org\/10.1093\/ckj\/sfaf260.","journal-title":"Clin Kidney J"},{"issue":"15","key":"3758_CR13","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/j.jacc.2025.12.015","volume":"87","author":"F Zannad","year":"2026","unstructured":"Zannad F, Khan MS, Bansal N, et al. MASLD, MASH, and the CKM spectrum: a roadmap for multiorgan clinical trial design. J Am Coll Cardiol. 2026;87(15):2006\u201333. https:\/\/doi.org\/10.1016\/j.jacc.2025.12.015.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"3758_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3390\/biom15020213","volume":"15","author":"N Theodorakis","year":"2025","unstructured":"Theodorakis N, Nikolaou M. From cardiovascular-kidney-metabolic syndrome to cardiovascular-renal-hepatic-metabolic syndrome: proposing an expanded framework. Biomolecules. 2025;15(2):213. https:\/\/doi.org\/10.3390\/biom15020213.","journal-title":"Biomolecules"},{"key":"3758_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-025-10013-6","author":"H Bian","year":"2026","unstructured":"Bian H, Ma J, Qu S, et al. The evolving concept from cardiovascular-kidney-metabolic syndrome to metabolic associated liver-cardiovascular-kidney syndrome: insights from endocrinology. Rev Endocr Metab Disord. 2026. https:\/\/doi.org\/10.1007\/s11154-025-10013-6.","journal-title":"Rev Endocr Metab Disord"},{"issue":"16","key":"3758_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.125.043173","volume":"14","author":"W Kawaharata","year":"2025","unstructured":"Kawaharata W, Tanaka M, Sato T, et al. Incorporation of metabolic dysfunction-associated steatotic liver disease in the health stage of cardiovascular-kidney-metabolic syndrome improves predictive ability for coronary artery disease in a Japanese general population. J Am Heart Assoc. 2025;14(16):e043173. https:\/\/doi.org\/10.1161\/jaha.125.043173.","journal-title":"J Am Heart Assoc"},{"key":"3758_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1663353","volume":"16","author":"P Iglesias","year":"2025","unstructured":"Iglesias P. The endocrine role of hepatokines: implications for human health and disease. Front Endocrinol (Lausanne). 2025;16:1663353. https:\/\/doi.org\/10.3389\/fendo.2025.1663353.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3758_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115807","author":"MS McGrath","year":"2024","unstructured":"McGrath MS, Wentworth BJ. The renin-angiotensin system in liver disease. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25115807.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"3758_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26157527","volume":"25","author":"N Morat","year":"2025","unstructured":"Morat N, Civieri G, Spezia M, et al. Angiotensin II and atherosclerosis: a new cardiovascular risk factor beyond hypertension. Int J Mol Sci. 2025;25(11):5807. https:\/\/doi.org\/10.3390\/ijms26157527.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3758_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12964-025-02625-x","volume":"24","author":"Y Zhang","year":"2026","unstructured":"Zhang Y, Sun C, Wang Y, et al. Targeting gut-liver-kidney axis: microbiota-derived metabolites and therapeutic implications. Cell Commun Signal. 2026;24(1):107. https:\/\/doi.org\/10.1186\/s12964-025-02625-x.","journal-title":"Cell Commun Signal"},{"key":"3758_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2026.101438","volume":"26","author":"Z Cao","year":"2026","unstructured":"Cao Z, Chen B, Zhou J, et al. Liver fibrosis biomarkers as a prognostic tool beyond the defining components in cardiovascular-kidney-metabolic syndrome. Am J Prev Cardiol. 2026;26:101438. https:\/\/doi.org\/10.1016\/j.ajpc.2026.101438.","journal-title":"Am J Prev Cardiol"},{"key":"3758_CR22","unstructured":"Pinkerton JV. Menopause MSD Manual Professional Edition: MSD Manual; 2023. updated 2023\/07. https:\/\/www.msdmanuals.com\/professional\/gynecology-and-obstetrics\/menopause\/menopause. Accessed 28 May 2026."},{"issue":"5","key":"3758_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.101229","volume":"297","author":"M Varghese","year":"2021","unstructured":"Varghese M, Griffin C, Abrishami S, et al. Sex hormones regulate metainflammation in diet-induced obesity in mice. J Biol Chem. 2021;297(5):101229. https:\/\/doi.org\/10.1016\/j.jbc.2021.101229.","journal-title":"J Biol Chem"},{"key":"3758_CR24","doi-asserted-by":"publisher","first-page":"174550572513768","DOI":"10.1177\/17455057251376883","volume":"21","author":"P Jancova","year":"2025","unstructured":"Jancova P, Ismail K, Vistejnova L. Relationship between MASLD and women\u2019s health: a review. Womens Health (Lond). 2025;21:17455057251376884. https:\/\/doi.org\/10.1177\/17455057251376883.","journal-title":"Womens Health (Lond)"},{"key":"3758_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156081","volume":"163","author":"ZA Kipp","year":"2025","unstructured":"Kipp ZA, Badmus OO, Stec DE, Hall B, Hinds TD Jr. Bilirubin bioconversion to urobilin in the gut-liver-kidney axis: a biomarker for insulin resistance in the cardiovascular-kidney-metabolic (CKM) syndrome. Metabolism. 2025;163:156081. https:\/\/doi.org\/10.1016\/j.metabol.2024.156081.","journal-title":"Metabolism"},{"key":"3758_CR26","doi-asserted-by":"publisher","first-page":"1554458","DOI":"10.3389\/fmicb.2025.1554458","volume":"16","author":"DL Fei","year":"2025","unstructured":"Fei DL, Liu Y, Liu J, Yu Z, Dong JL. Gut microbiota and the \u201cgut-liver-kidney axis\u201d theory: from mechanisms to therapeutics. Front Microbiol. 2025;16:1554458. https:\/\/doi.org\/10.3389\/fmicb.2025.1554458.","journal-title":"Front Microbiol"},{"issue":"2","key":"3758_CR27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.22074\/cellj.2023.2007757.1376","volume":"26","author":"NK Rad","year":"2024","unstructured":"Rad NK, Heydari Z, Tamimi AH, et al. Review on kidney-liver crosstalk: pathophysiology of their disorders. Cell J. 2024;26(2):98\u2013111. https:\/\/doi.org\/10.22074\/cellj.2023.2007757.1376.","journal-title":"Cell J"},{"issue":"13","key":"3758_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137037","volume":"325","author":"M Hole\u010dek","year":"2024","unstructured":"Hole\u010dek M. Origin and roles of alanine and glutamine in gluconeogenesis in the liver, kidneys, and small intestine under physiological and pathological conditions. Int J Mol Sci. 2024;325(13):7037. https:\/\/doi.org\/10.3390\/ijms25137037.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"3758_CR29","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.4239\/wjd.v14.i7.1049","volume":"14","author":"B Sahoo","year":"2023","unstructured":"Sahoo B, Srivastava M, Katiyar A, Ecelbarger C, Tiwari S. Liver or kidney: who has the oar in the gluconeogenesis boat and when? World J Diabetes. 2023;14(7):1049\u201356. https:\/\/doi.org\/10.4239\/wjd.v14.i7.1049.","journal-title":"World J Diabetes"},{"key":"3758_CR30","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/B978-0-08-027350-1.50041-4","volume-title":"Gastrointestinal defence mechanisms","author":"CD Klaassen","year":"1981","unstructured":"Klaassen CD. Biliary excretion of xenobiotics. In: M\u00f3zsik G, H\u00e4nninen O, J\u00e1vor T, editors. Gastrointestinal defence mechanisms. Elmsford: Pergamon; 1981. p. 555\u201365."},{"key":"3758_CR31","volume-title":"StatPearls","author":"A Garza","year":"2026","unstructured":"Garza A, Park S, Kocz R. Drug elimination. In: StatPearls. Treasure Island: StatPearls; 2026."},{"key":"3758_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-nutr-111120-111518","volume":"41","author":"P Puchalska","year":"2021","unstructured":"Puchalska P, Crawford PA. Metabolic and signaling roles of ketone bodies in health and disease. Annu Rev Nutr. 2021;41:49\u201377. https:\/\/doi.org\/10.1146\/annurev-nutr-111120-111518.","journal-title":"Annu Rev Nutr"},{"issue":"9","key":"3758_CR33","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.34067\/kid.0000000931","volume":"6","author":"G Arthur","year":"2025","unstructured":"Arthur G, Adenawoola MI, Wahba S, Montgomery BS, Stec DE. Role of liver-derived ketones, hepatokines, and metabolites in the regulation of renal function. Kidney 360. 2025;6(9):1609\u201317. https:\/\/doi.org\/10.34067\/kid.0000000931.","journal-title":"Kidney 360"},{"issue":"21","key":"3758_CR34","doi-asserted-by":"publisher","first-page":"13320","DOI":"10.3390\/ijms232113320","volume":"23","author":"A Lonardo","year":"2022","unstructured":"Lonardo A, Mantovani A, Targher G, Baffy G. Nonalcoholic fatty liver disease and chronic kidney disease: epidemiology, pathogenesis, and clinical and research implications. Int J Mol Sci. 2022;23(21):13320. https:\/\/doi.org\/10.3390\/ijms232113320.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3758_CR35","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/mcg.0000000000002332","volume":"60","author":"S Chandna","year":"2026","unstructured":"Chandna S, Baniqued MR, Harmon R, Chan P, Wang J, Patel JH. Hepatorenal syndrome in focus: emerging diagnostic criteria and current therapeutic approaches. J Clin Gastroenterol. 2026;60(5):385\u201393. https:\/\/doi.org\/10.1097\/mcg.0000000000002332.","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"3758_CR36","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s12325-025-03121-x","volume":"42","author":"K Bagheri Lankarani","year":"2025","unstructured":"Bagheri Lankarani K, Jamalinia M, Zare F, Heydari ST, Ardekani A, Lonardo A. Liver-kidney-metabolic health, sex, and menopause impact total scores and monovessel vs. multivessel coronary artery calcification. Adv Ther. 2025;42(4):1729\u201344. https:\/\/doi.org\/10.1007\/s12325-025-03121-x.","journal-title":"Adv Ther"},{"issue":"6","key":"3758_CR37","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1007\/s11427-025-3193-9","volume":"69","author":"XD Zhou","year":"2026","unstructured":"Zhou XD, Fan QY, Targher G, et al. MASLD as a systemic metabolic disease: expanding the scope of cardiovascular-kidney-metabolic (CKM) syndrome. Sci China Life Sci. 2026;69(6):1950\u201365. https:\/\/doi.org\/10.1007\/s11427-025-3193-9.","journal-title":"Sci China Life Sci"},{"issue":"10","key":"3758_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12100954","volume":"12","author":"HG Jeong","year":"2022","unstructured":"Jeong HG, Park H. Metabolic disorders in menopause. Metabolites. 2022;12(10):954. https:\/\/doi.org\/10.3390\/metabo12100954.","journal-title":"Metabolites"},{"key":"3758_CR39","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/978-981-96-0239-1_13","volume-title":"Management of menopause: a guide for practitioners","author":"S Agrawal","year":"2024","unstructured":"Agrawal S, Panda S, Kashibhatla J. Menopause and metabolic syndrome. In: Garg R, editor. Management of menopause: a guide for practitioners. Singapore: Springer Nature Singapore; 2024. p. 147\u201364."},{"issue":"12","key":"3758_CR40","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51287","volume":"15","author":"V Motlani","year":"2023","unstructured":"Motlani V, Motlani G, Pamnani S, Sahu A, Acharya N. Endocrine changes in postmenopausal women: a comprehensive view. Cureus. 2023;15(12):e51287. https:\/\/doi.org\/10.7759\/cureus.51287.","journal-title":"Cureus"},{"key":"3758_CR41","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2147\/ijwh.S460645","volume":"16","author":"K Erdo\u011fan","year":"2024","unstructured":"Erdo\u011fan K, Sanlier N. Metabolic syndrome and menopause: the impact of menopause duration on risk factors and components. Int J Womens Health. 2024;16:1249\u201356. https:\/\/doi.org\/10.2147\/ijwh.S460645.","journal-title":"Int J Womens Health"},{"issue":"1","key":"3758_CR42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41581-023-00717-w","volume":"20","author":"VA Dines","year":"2024","unstructured":"Dines VA, Garovic VD. Menopause and chronic kidney disease. Nat Rev Nephrol. 2024;20(1):4\u20135. https:\/\/doi.org\/10.1038\/s41581-023-00717-w.","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"3758_CR43","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/gme.0000000000001755","volume":"28","author":"S Samargandy","year":"2021","unstructured":"Samargandy S, Matthews KA, Brooks MM, et al. Abdominal visceral adipose tissue over the menopause transition and carotid atherosclerosis: the SWAN heart study. Menopause. 2021;28(6):626\u201333. https:\/\/doi.org\/10.1097\/gme.0000000000001755.","journal-title":"Menopause"},{"issue":"5","key":"3758_CR44","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124865","volume":"4","author":"GA Greendale","year":"2019","unstructured":"Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865.\u00a0https:\/\/doi.org\/10.1172\/jci.insight.124865.","journal-title":"JCI Insight"},{"issue":"4","key":"3758_CR45","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1210\/jc.2008-0701","volume":"94","author":"CG Lee","year":"2009","unstructured":"Lee CG, Carr MC, Murdoch SJ, et al. Adipokines, inflammation, and visceral adiposity across the menopausal transition: a prospective study. J Clin Endocrinol Metab. 2009;94(4):1104\u201310. https:\/\/doi.org\/10.1210\/jc.2008-0701.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"3758_CR46","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40618-019-01168-6","volume":"43","author":"G Palla","year":"2020","unstructured":"Palla G, Ram\u00edrez-Mor\u00e1n C, Montt-Guevara MM, et al. Perimenopause, body fat, metabolism and menopausal symptoms in relation to serum markers of adiposity, inflammation and digestive metabolism. J Endocrinol Invest. 2020;43(6):809\u201320. https:\/\/doi.org\/10.1007\/s40618-019-01168-6.","journal-title":"J Endocrinol Invest"},{"issue":"15","key":"3758_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26157074","volume":"26","author":"D Pinto da Costa Viana","year":"2025","unstructured":"Pinto da Costa Viana D, Caseri C\u00e2mara L, Borges Palau R. Menopause as a critical turning point in lipedema: the estrogen receptor imbalance, intracrine estrogen, and adipose tissue dysfunction model. Int J Mol Sci. 2025;26(15):7074. https:\/\/doi.org\/10.3390\/ijms26157074.","journal-title":"Int J Mol Sci"},{"key":"3758_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1682231","volume":"16","author":"AA Lee","year":"2025","unstructured":"Lee AA, Den Hartigh LJ. Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan. Front Endocrinol (Lausanne). 2025;16:1682231. https:\/\/doi.org\/10.3389\/fendo.2025.1682231.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"13","key":"3758_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26136382","volume":"26","author":"R Weiskirchen","year":"2025","unstructured":"Weiskirchen R, Lonardo A. The ovary-liver axis: molecular science and epidemiology. Int J Mol Sci. 2025;26(13):6382. https:\/\/doi.org\/10.3390\/ijms26136382.","journal-title":"Int J Mol Sci"},{"key":"3758_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104303","volume":"85","author":"KM Bermingham","year":"2022","unstructured":"Bermingham KM, Linenberg I, Hall WL, et al. Menopause is associated with postprandial metabolism, metabolic health and lifestyle: the ZOE PREDICT study. EBioMedicine. 2022;85:104303. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104303.","journal-title":"EBioMedicine"},{"key":"3758_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2024.108024","volume":"186","author":"SA Polyzos","year":"2024","unstructured":"Polyzos SA, Goulis DG. Menopause and metabolic dysfunction-associated steatotic liver disease. Maturitas. 2024;186:108024. https:\/\/doi.org\/10.1016\/j.maturitas.2024.108024.","journal-title":"Maturitas"},{"issue":"1","key":"3758_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47687-6","volume":"15","author":"W Yang","year":"2024","unstructured":"Yang W, Jiang W, Liao W, et al. An estrogen receptor \u03b1-derived peptide improves glucose homeostasis during obesity. Nat Commun. 2024;15(1):3410. https:\/\/doi.org\/10.1038\/s41467-024-47687-6.","journal-title":"Nat Commun"},{"issue":"9","key":"3758_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare13091062","volume":"13","author":"MJ Choi","year":"2025","unstructured":"Choi MJ, Yu J. Menopause and diabetes risk along with trajectory of \u03b2-cell function and insulin sensitivity: a community-based cohort study. Healthcare (Basel). 2025;13(9):1062. https:\/\/doi.org\/10.3390\/healthcare13091062.","journal-title":"Healthcare (Basel)"},{"issue":"3","key":"3758_CR54","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s11154-025-09994-1","volume":"27","author":"I Gonz\u00e1lez-Garc\u00eda","year":"2025","unstructured":"Gonz\u00e1lez-Garc\u00eda I, Xu Y. Hypothalamic actions of estrogens in the regulation of energy and glucose homeostasis. Rev Endocr Metab Disord. 2026;27(3):547\u201359. https:\/\/doi.org\/10.1007\/s11154-025-09994-1.","journal-title":"Rev Endocr Metab Disord"},{"key":"3758_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.119213","volume":"405","author":"JAE van Oortmerssen","year":"2025","unstructured":"van Oortmerssen JAE, Mulder J, Kavousi M, Roeters van Lennep JE. Lipid metabolism in women: a review. Atherosclerosis. 2025;405:119213. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119213.","journal-title":"Atherosclerosis"},{"issue":"7","key":"3758_CR56","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/gme.0000000000001532","volume":"27","author":"V Inaraja","year":"2020","unstructured":"Inaraja V, Thuissard I, Andreu-Vazquez C, Jodar E. Lipid profile changes during the menopausal transition. Menopause. 2020;27(7):780\u20137. https:\/\/doi.org\/10.1097\/gme.0000000000001532.","journal-title":"Menopause"},{"issue":"22","key":"3758_CR57","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.123.030388","volume":"12","author":"B Wu","year":"2023","unstructured":"Wu B, Fan B, Qu Y, et al. Trajectories of blood lipids profile in midlife women: does menopause matter? J Am Heart Assoc. 2023;12(22):e030388. https:\/\/doi.org\/10.1161\/jaha.123.030388.","journal-title":"J Am Heart Assoc"},{"issue":"25","key":"3758_CR58","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.jacc.2009.10.009","volume":"54","author":"KA Matthews","year":"2009","unstructured":"Matthews KA, Crawford SL, Chae CU, et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol. 2009;54(25):2366\u201373. https:\/\/doi.org\/10.1016\/j.jacc.2009.10.009.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"3758_CR59","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jhep.2024.04.032","volume":"81","author":"S Della Torre","year":"2024","unstructured":"Della Torre S, Cherubini A, Valenti L. Estrogen receptor alpha in the female liver: Dr. Jekyll and Mr. Hyde. J Hepatol. 2024;81(4):763\u20135. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.032.","journal-title":"J Hepatol"},{"issue":"6","key":"3758_CR60","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1210\/endrev\/bnaf018","volume":"46","author":"J Dong","year":"2025","unstructured":"Dong J, Dennis K, Venkatakrishnan R, Hodson L, Tomlinson JW. The impact of estrogen deficiency on liver metabolism: implications for hormone replacement therapy. Endocr Rev. 2025;46(6):790\u2013809. https:\/\/doi.org\/10.1210\/endrev\/bnaf018.","journal-title":"Endocr Rev"},{"issue":"12","key":"3758_CR61","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.ebiom.2015.11.002","volume":"2","author":"LP Klosinski","year":"2015","unstructured":"Klosinski LP, Yao J, Yin F, et al. White matter lipids as a ketogenic fuel supply in aging female brain: implications for Alzheimer\u2019s disease. EBioMedicine. 2015;2(12):1888\u2013904. https:\/\/doi.org\/10.1016\/j.ebiom.2015.11.002.","journal-title":"EBioMedicine"},{"issue":"4","key":"3758_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13040855","volume":"13","author":"I Milani","year":"2025","unstructured":"Milani I, Chinucci M, Leonetti F, Capoccia D. MASLD: prevalence, mechanisms, and sex-based therapies in postmenopausal women. Biomedicines. 2025;13(4):855. https:\/\/doi.org\/10.3390\/biomedicines13040855.","journal-title":"Biomedicines"},{"key":"3758_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2024.108145","volume":"192","author":"EC Cevik","year":"2025","unstructured":"Cevik EC, Erel CT, Ozcivit Erkan IB, et al. Chronic kidney disease and menopausal health: an EMAS clinical guide. Maturitas. 2025;192:108145. https:\/\/doi.org\/10.1016\/j.maturitas.2024.108145.","journal-title":"Maturitas"},{"issue":"3","key":"3758_CR64","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nrneph.2017.181","volume":"14","author":"JJ Carrero","year":"2018","unstructured":"Carrero JJ, Hecking M, Chesnaye NC, Jager KJ. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nat Rev Nephrol. 2018;14(3):151\u201364. https:\/\/doi.org\/10.1038\/nrneph.2017.181.","journal-title":"Nat Rev Nephrol"},{"issue":"7","key":"3758_CR65","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.mayocp.2018.12.024","volume":"94","author":"J Neugarten","year":"2019","unstructured":"Neugarten J, Golestaneh L. Influence of sex on the progression of chronic kidney disease. Mayo Clin Proc. 2019;94(7):1339\u201356. https:\/\/doi.org\/10.1016\/j.mayocp.2018.12.024.","journal-title":"Mayo Clin Proc"},{"key":"3758_CR66","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.maturitas.2021.06.013","volume":"152","author":"ZM Roa-D\u00edaz","year":"2021","unstructured":"Roa-D\u00edaz ZM, Raguindin PF, Bano A, Laine JE, Muka T, Glisic M. Menopause and cardiometabolic diseases: what we (don\u2019t) know and why it matters. Maturitas. 2021;152:48\u201356. https:\/\/doi.org\/10.1016\/j.maturitas.2021.06.013.","journal-title":"Maturitas"},{"issue":"1","key":"3758_CR67","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/oby.23289","volume":"30","author":"KL Marlatt","year":"2022","unstructured":"Marlatt KL, Pitynski-Miller DR, Gavin KM, et al. Body composition and cardiometabolic health across the menopause transition. Obesity (Silver Spring). 2022;30(1):14\u201327. https:\/\/doi.org\/10.1002\/oby.23289.","journal-title":"Obesity (Silver Spring)"},{"key":"3758_CR68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4172\/2380-9477.1000187","volume":"12","author":"H Zhang","year":"2024","unstructured":"Zhang H. Effect of hormonal changes on drug metabolism in women. J Pharm Sci Emerg Drugs. 2024;12:3. https:\/\/doi.org\/10.4172\/2380-9477.1000187.","journal-title":"J Pharm Sci Emerg Drugs"},{"issue":"1","key":"3758_CR69","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3109\/13697137.2010.498593","volume":"14","author":"SM Kim","year":"2011","unstructured":"Kim SM, Kim SH, Lee JR, et al. The effects of hormone therapy on metabolic risk factors in postmenopausal Korean women. Climacteric. 2011;14(1):66\u201374. https:\/\/doi.org\/10.3109\/13697137.2010.498593.","journal-title":"Climacteric"},{"key":"3758_CR70","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.maturitas.2018.12.012","volume":"121","author":"JE Kim","year":"2019","unstructured":"Kim JE, Choi J, Park J, et al. Associations of postmenopausal hormone therapy with metabolic syndrome among diabetic and non-diabetic women. Maturitas. 2019;121:76\u201382. https:\/\/doi.org\/10.1016\/j.maturitas.2018.12.012.","journal-title":"Maturitas"},{"issue":"3","key":"3758_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2025.104432","volume":"36","author":"AV Mattioli","year":"2026","unstructured":"Mattioli AV, Cocchi C, Selleri V, et al. Hormone replacement therapy and serum uric acid in postmenopausal women: a cardiometabolic insight. Nutr Metab Cardiovasc Dis. 2026;36(3):104432. https:\/\/doi.org\/10.1016\/j.numecd.2025.104432.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"6","key":"3758_CR72","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/13697137.2025.2509844","volume":"28","author":"T Li","year":"2025","unstructured":"Li T, Jiang NS, Kaskey J, Schnatz PF, Nudy M. Hormone therapy and insulin resistance in non-diabetic postmenopausal women: a systematic review and meta-analysis. Climacteric. 2025;28(6):673\u201381. https:\/\/doi.org\/10.1080\/13697137.2025.2509844.","journal-title":"Climacteric"},{"issue":"5","key":"3758_CR73","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1463-1326.2005.00545.x","volume":"8","author":"SR Salpeter","year":"2006","unstructured":"Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006;8(5):538\u201354. https:\/\/doi.org\/10.1111\/j.1463-1326.2005.00545.x.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"3758_CR74","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/oby.20653","volume":"22","author":"RE Van Pelt","year":"2014","unstructured":"Van Pelt RE, Gozansky WS, Wolfe P, et al. Estrogen or raloxifene during postmenopausal weight loss: adiposity and cardiometabolic outcomes. Obesity (Silver Spring). 2014;22(4):1024\u201331. https:\/\/doi.org\/10.1002\/oby.20653.","journal-title":"Obesity (Silver Spring)"},{"issue":"12","key":"3758_CR75","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1097\/gme.0b013e31825a3344","volume":"19","author":"M Ahtiainen","year":"2012","unstructured":"Ahtiainen M, Alen M, P\u00f6ll\u00e4nen E, et al. Hormone therapy is associated with better body composition and adipokine\/glucose profiles: a study with monozygotic co-twin control design. Menopause. 2012;19(12):1329\u201335. https:\/\/doi.org\/10.1097\/gme.0b013e31825a3344.","journal-title":"Menopause"},{"issue":"8","key":"3758_CR76","first-page":"367","volume":"77","author":"S Carranza Lira","year":"2009","unstructured":"Carranza Lira S, Guerrero Mills L, Castro A. Frequency of metabolic syndrome in Mexican postmenopausal women and its relation with the hormonal therapy. Ginecol Obstet Mex. 2009;77(8):367\u201371.","journal-title":"Ginecol Obstet Mex"},{"issue":"9","key":"3758_CR77","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1097\/gme.0000000000000657","volume":"23","author":"S Ramesh","year":"2016","unstructured":"Ramesh S, Mann MC, Holroyd-Leduc JM, et al. Hormone therapy and clinical and surrogate cardiovascular endpoints in women with chronic kidney disease: a systematic review and meta-analysis. Menopause. 2016;23(9):1028\u201337. https:\/\/doi.org\/10.1097\/gme.0000000000000657.","journal-title":"Menopause"},{"issue":"23","key":"3758_CR78","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.4103\/0366-6999.194646","volume":"129","author":"W Xue","year":"2016","unstructured":"Xue W, Deng Y, Wang YF, Sun AJ. Effect of half-dose and standard-dose conjugated equine estrogens combined with natural progesterone or dydrogesterone on components of metabolic syndrome in healthy postmenopausal women: a randomized controlled trial. Chin Med J (Engl). 2016;129(23):2773\u20139. https:\/\/doi.org\/10.4103\/0366-6999.194646.","journal-title":"Chin Med J (Engl)"},{"issue":"9","key":"3758_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17091388","volume":"17","author":"MA S\u00e1nchez-Rodr\u00edguez","year":"2016","unstructured":"S\u00e1nchez-Rodr\u00edguez MA, Zacar\u00edas-Flores M, Castrej\u00f3n-Delgado L, Ruiz-Rodr\u00edguez AK, Mendoza-N\u00fa\u00f1ez VM. Effects of hormone therapy on oxidative stress in postmenopausal women with metabolic syndrome. Int J Mol Sci. 2016;17(9):1388. https:\/\/doi.org\/10.3390\/ijms17091388.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3758_CR80","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11357-013-9554-7","volume":"36","author":"MR Rizzo","year":"2014","unstructured":"Rizzo MR, Leo S, De Franciscis P, Colacurci N, Paolisso G. Short-term effects of low-dose estrogen\/drospirenone vs low-dose estrogen\/dydrogesterone on glycemic fluctuations in postmenopausal women with metabolic syndrome. Age (Dordr). 2014;36(1):265\u201374. https:\/\/doi.org\/10.1007\/s11357-013-9554-7.","journal-title":"Age (Dordr)"},{"issue":"2","key":"3758_CR81","first-page":"233","volume":"40","author":"P De Franciscis","year":"2013","unstructured":"De Franciscis P, Mainini G, Labriola D, et al. Low-dose estrogen and drospirenone combination: effects on metabolism and endothelial function in postmenopausal women with metabolic syndrome. Clin Exp Obstet Gynecol. 2013;40(2):233\u20135.","journal-title":"Clin Exp Obstet Gynecol"},{"issue":"2","key":"3758_CR82","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1210\/clinem\/dgae458","volume":"110","author":"N Hetem\u00e4ki","year":"2025","unstructured":"Hetem\u00e4ki N, Robciuc A, Vihma V, et al. Adipose tissue sex steroids in postmenopausal women with and without menopausal hormone therapy. J Clin Endocrinol Metab. 2025;110(2):511\u201322. https:\/\/doi.org\/10.1210\/clinem\/dgae458.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"3758_CR83","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/gme.0000000000002278","volume":"31","author":"K Kantarci","year":"2024","unstructured":"Kantarci K, Tosakulwong N, Lesnick TG, et al. Cardiometabolic outcomes in Kronos Early Estrogen Prevention Study continuation: 14-year follow-up of a hormone therapy trial. Menopause. 2024;31(1):10\u20137. https:\/\/doi.org\/10.1097\/gme.0000000000002278.","journal-title":"Menopause"},{"issue":"3","key":"3758_CR84","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3109\/09513590.2010.487613","volume":"27","author":"JL Cuadros","year":"2011","unstructured":"Cuadros JL, Fern\u00e1ndez-Alonso AM, Chedraui P, Cuadros AM, Sabatel RM, P\u00e9rez-L\u00f3pez FR. Metabolic and hormonal parameters in post-menopausal women 10\u00a0years after transdermal oestradiol treatment, alone or combined to micronized oral progesterone. Gynecol Endocrinol. 2011;27(3):156\u201362. https:\/\/doi.org\/10.3109\/09513590.2010.487613.","journal-title":"Gynecol Endocrinol"},{"issue":"12","key":"3758_CR85","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1210\/jc.2015-3084","volume":"100","author":"RI Pereira","year":"2015","unstructured":"Pereira RI, Casey BA, Swibas TA, Erickson CB, Wolfe P, Van Pelt RE. Timing of estradiol treatment after menopause may determine benefit or harm to insulin action. J Clin Endocrinol Metab. 2015;100(12):4456\u201362. https:\/\/doi.org\/10.1210\/jc.2015-3084.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3758_CR86","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1590\/s0004-28032013000200032","volume":"50","author":"GS Florentino","year":"2013","unstructured":"Florentino GS, Cotrim HP, Vilar CP, Florentino AV, Guimar\u00e3es GM, Barreto VS. Nonalcoholic fatty liver disease in menopausal women. Arq Gastroenterol. 2013;50(3):180\u20135. https:\/\/doi.org\/10.1590\/s0004-28032013000200032.","journal-title":"Arq Gastroenterol"},{"issue":"4","key":"3758_CR87","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70562","volume":"46","author":"AE Henney","year":"2026","unstructured":"Henney AE, Wilson J, Riley DR, Alam U, Cuthbertson DJ. Effect of hormone replacement therapy on liver and cardiometabolic outcomes in peri-menopausal MASLD. Liver Int. 2026;46(4):e70562. https:\/\/doi.org\/10.1111\/liv.70562.","journal-title":"Liver Int"},{"issue":"6","key":"3758_CR88","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.cgh.2020.08.012","volume":"19","author":"J Wang","year":"2021","unstructured":"Wang J, Wu AH, Stanczyk FZ, et al. Associations between reproductive and hormone-related factors and risk of nonalcoholic fatty liver disease in a multiethnic population. Clin Gastroenterol Hepatol. 2021;19(6):1258-66.e1. https:\/\/doi.org\/10.1016\/j.cgh.2020.08.012.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"3758_CR89","doi-asserted-by":"publisher","first-page":"469.e1","DOI":"10.1016\/j.ajog.2025.04.007","volume":"233","author":"MY Miao","year":"2025","unstructured":"Miao MY, Han WW, Lyu JQ, et al. Female reproductive factors and metabolic dysfunction-associated steatotic liver disease: an integrated analysis of population cohort, liver imaging, and genetic data. Am J Obstet Gynecol. 2025;233(5):469.e1-469.e54. https:\/\/doi.org\/10.1016\/j.ajog.2025.04.007.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"3758_CR90","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cgh.2016.07.034","volume":"15","author":"JD Yang","year":"2017","unstructured":"Yang JD, Abdelmalek MF, Guy CD, et al. Patient sex, reproductive status, and synthetic hormone use associate with histologic severity of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2017;15(1):127-31.e2. https:\/\/doi.org\/10.1016\/j.cgh.2016.07.034.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"3758_CR91","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/hep.28514","volume":"64","author":"JS Klair","year":"2016","unstructured":"Klair JS, Yang JD, Abdelmalek MF, et al. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology. 2016;64(1):85\u201391. https:\/\/doi.org\/10.1002\/hep.28514.","journal-title":"Hepatology"},{"issue":"1","key":"3758_CR92","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3109\/13697137.2012.662251","volume":"16","author":"R Barsalani","year":"2013","unstructured":"Barsalani R, Riesco E, Lavoie JM, Dionne IJ. Effect of exercise training and isoflavones on hepatic steatosis in overweight postmenopausal women. Climacteric. 2013;16(1):88\u201395. https:\/\/doi.org\/10.3109\/13697137.2012.662251.","journal-title":"Climacteric"},{"issue":"1","key":"3758_CR93","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1365-2265.2006.02543.x","volume":"65","author":"J McKenzie","year":"2006","unstructured":"McKenzie J, Fisher BM, Jaap AJ, Stanley A, Paterson K, Sattar N. Effects of HRT on liver enzyme levels in women with type\u00a02 diabetes: a randomized placebo-controlled trial. Clin Endocrinol (Oxf). 2006;65(1):40\u20134. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02543.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"3758_CR94","doi-asserted-by":"publisher","DOI":"10.1080\/0886022x.2026.2665868","volume":"48","author":"Q Wang","year":"2026","unstructured":"Wang Q, Li R, Liu YC, Chang J. Association of reproductive factors and chronic kidney disease in postmenopausal women: results from the U.S. National Health and Nutrition Examination Survey 1999 - 2020. Ren Fail. 2026;48(1):2665868. https:\/\/doi.org\/10.1080\/0886022x.2026.2665868.","journal-title":"Ren Fail"},{"issue":"2","key":"3758_CR95","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40620-024-02099-z","volume":"38","author":"S Cho","year":"2025","unstructured":"Cho S, Kim M, Jung S, et al. Potential benefits of hormone replacement therapy on cardiovascular and kidney outcomes in postmenopausal women with chronic kidney disease. J Nephrol. 2025;38(2):491\u2013501. https:\/\/doi.org\/10.1007\/s40620-024-02099-z.","journal-title":"J Nephrol"},{"issue":"1","key":"3758_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93847-9","volume":"11","author":"SY Ahn","year":"2021","unstructured":"Ahn SY, Choi YJ, Kim J, Ko GJ, Kwon YJ, Han K. The beneficial effects of menopausal hormone therapy on renal survival in postmenopausal Korean women from a nationwide health survey. Sci Rep. 2021;11(1):15418. https:\/\/doi.org\/10.1038\/s41598-021-93847-9.","journal-title":"Sci Rep"},{"issue":"6","key":"3758_CR97","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/ijcp.12597","volume":"69","author":"E Vitolo","year":"2015","unstructured":"Vitolo E, Comassi M, Caputo MT, Solini A. Hormone replacement therapy, renal function and heart ultrasonographic parameters in postmenopausal women: an observational study. Int J Clin Pract. 2015;69(6):632\u20137. https:\/\/doi.org\/10.1111\/ijcp.12597.","journal-title":"Int J Clin Pract"},{"issue":"6","key":"3758_CR98","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1007\/s00404-012-2215-8","volume":"285","author":"I Kaygusuz","year":"2012","unstructured":"Kaygusuz I, Gumus II, Yuvaci HU, Kasapo\u011flu B, Carlioglu A. Does hormone replacement therapy have beneficial effects on renal functions in menopausal women? Arch Gynecol Obstet. 2012;285(6):1643\u20136. https:\/\/doi.org\/10.1007\/s00404-012-2215-8.","journal-title":"Arch Gynecol Obstet"},{"issue":"12","key":"3758_CR99","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1093\/ndt\/gfp321","volume":"24","author":"EL Schopick","year":"2009","unstructured":"Schopick EL, Fisher ND, Lin J, Forman JP, Curhan GC. Post-menopausal hormone use and albuminuria. Nephrol Dial Transplant. 2009;24(12):3739\u201344. https:\/\/doi.org\/10.1093\/ndt\/gfp321.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"3758_CR100","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1097\/gme.0b013e3181fca9c4","volume":"18","author":"MM Fung","year":"2011","unstructured":"Fung MM, Poddar S, Bettencourt R, Jassal SK, Barrett-Connor E. A cross-sectional and 10-year prospective study of postmenopausal estrogen therapy and blood pressure, renal function, and albuminuria: the Rancho Bernardo Study. Menopause. 2011;18(6):629\u201337. https:\/\/doi.org\/10.1097\/gme.0b013e3181fca9c4.","journal-title":"Menopause"},{"issue":"3","key":"3758_CR101","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/ki.2008.205","volume":"74","author":"SB Ahmed","year":"2008","unstructured":"Ahmed SB, Culleton BF, Tonelli M, et al. Oral estrogen therapy in postmenopausal women is associated with loss of kidney function. Kidney Int. 2008;74(3):370\u20136. https:\/\/doi.org\/10.1038\/ki.2008.205.","journal-title":"Kidney Int"},{"issue":"6","key":"3758_CR102","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/j.fertnstert.2006.04.043","volume":"86","author":"MC Chu","year":"2006","unstructured":"Chu MC, Cosper P, Nakhuda GS, Lobo RA. A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome. Fertil Steril. 2006;86(6):1669\u201375. https:\/\/doi.org\/10.1016\/j.fertnstert.2006.04.043.","journal-title":"Fertil Steril"},{"issue":"5","key":"3758_CR103","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/01.gme.0000133076.09175.6d","volume":"11","author":"YA Shakir","year":"2004","unstructured":"Shakir YA, Samsioe G, Nerbrand C, Lidfeldt J. Combined hormone therapy in postmenopausal women with features of metabolic syndrome. Results from a population-based study of Swedish women: Women\u2019s Health in the Lund Area study. Menopause. 2004;11(5):549\u201355. https:\/\/doi.org\/10.1097\/01.gme.0000133076.09175.6d.","journal-title":"Menopause"},{"issue":"1","key":"3758_CR104","doi-asserted-by":"publisher","DOI":"10.20517\/mtod.2021.05","volume":"1","author":"S Ballestri","year":"2021","unstructured":"Ballestri S, Mantovani A, Byrne CD, Lonardo A, Targher G. Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of observational studies. Metab Target Organ Damage. 2021;1(1):7. https:\/\/doi.org\/10.20517\/mtod.2021.05.","journal-title":"Metab Target Organ Damage"},{"issue":"1","key":"3758_CR105","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-04571-4","volume":"24","author":"P Pirrotte","year":"2025","unstructured":"Pirrotte P, Lovell B, Harlow SD, et al. Hepatic steatosis in postmenopausal women is characterized by distinct serum extracellular vesicle proteomic signatures. BMC Med. 2025;24(1):24. https:\/\/doi.org\/10.1186\/s12916-025-04571-4.","journal-title":"BMC Med"},{"key":"3758_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2026.05.001","author":"M Jamalinia","year":"2026","unstructured":"Jamalinia M, Targher G, Lonardo A. X-chromosome gene dosage shapes MASLD beyond sex hormones. Trends Endocrinol Metab. 2026. https:\/\/doi.org\/10.1016\/j.tem.2026.05.001.","journal-title":"Trends Endocrinol Metab"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03758-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03758-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03758-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T03:03:33Z","timestamp":1787367813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03758-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":106,"alternative-id":["3758"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03758-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mohamad Jamalinia is a member of the Advisory Board of\n                      Advances in Therapy\n                      , and Amedeo Lonardo is a member of the Editorial Board of\n                      Advances in Therapy\n                      . Amedeo Lonardo was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Ralf Weiskirchen has nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}